A Tutorial on Target-Mediated Drug Disposition (TMDD) Models

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2015 Jul 31

PMID 26225261

Citations 61

Authors

P Dua

E Hawkins

P H van der Graaf

Affiliations

Soon will be listed here.

Abstract

Target-mediated drug disposition (TMDD) is the phenomenon in which a drug binds with high affinity to its pharmacological target site (such as a receptor) to such an extent that this affects its pharmacokinetic characteristics.1 The aim of this Tutorial is to provide an introductory guide to the mathematical aspects of TMDD models for pharmaceutical researchers. Examples of Berkeley Madonna2 code for some models discussed in this Tutorial are provided in the Supplementary Materials.

Citing Articles

Quantifying antibody binding: techniques and therapeutic implications.

Lodge J, Kajtar L, Duxbury R, Hall D, Burley G, Cordy J MAbs. 2025; 17(1):2459795.

PMID: 39957177 PMC: 11834528. DOI: 10.1080/19420862.2025.2459795.

Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study.

Janus A, Dumas D, Le Douce J, Marie S, Pasculli G, Bambury P Neurol Ther. 2024; 14(1):357-377.

PMID: 39708220 PMC: 11762061. DOI: 10.1007/s40120-024-00691-w.

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.

Alasmari M, Albusaysi S, Elhefnawy M, Ali A, Altigani K, Almoslem M Saudi Pharm J. 2024; 32(12):102207.

PMID: 39697476 PMC: 11653594. DOI: 10.1016/j.jsps.2024.102207.

First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.

Yu H, Chen Y, Qi Y, Yang H, Cao G, Yang W CNS Neurosci Ther. 2024; 30(11):e70126.

PMID: 39592888 PMC: 11598743. DOI: 10.1111/cns.70126.

Local depletion of large molecule drugs due to target binding in tissue interstitial space.

Zasedateleva T, Schaller S, de Lange E, de Witte W CPT Pharmacometrics Syst Pharmacol. 2024; 13(12):2068-2086.

PMID: 39530200 PMC: 11646940. DOI: 10.1002/psp4.13262.

References

Marathe A, Peterson M, Mager D . Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008; 326(2):555-62. PMC: 2574593. DOI: 10.1124/jpet.108.137703. View

Davda J, Hansen R . Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010; 2(5):576-88. PMC: 2958579. DOI: 10.4161/mabs.2.5.12833. View

Eppler S, Combs D, Henry T, Lopez J, Ellis S, Yi J . A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 2002; 72(1):20-32. DOI: 10.1067/mcp.2002.126179. View

Lobo E, Soda D, Balthasar J . Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J Pharm Sci. 2003; 92(8):1665-76. DOI: 10.1002/jps.10432. View

Segrave A, Mager D, Charman S, Edwards G, Porter C . Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther. 2004; 309(3):1085-92. DOI: 10.1124/jpet.103.063289. View

Gibiansky L, Gibiansky E . Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn. 2010; 37(4):323-46. DOI: 10.1007/s10928-010-9163-3. View

Marathe A, Van Wart S, Mager D . Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2010; 38(2):223-35. PMC: 3157244. DOI: 10.1007/s10928-010-9190-0. View

Ait-Oudhia S, Scherrmann J, Krzyzanski W . Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J Pharmacol Exp Ther. 2010; 334(3):897-910. PMC: 2939674. DOI: 10.1124/jpet.110.167304. View

Jin F, Krzyzanski W . Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci. 2004; 6(1):E9. PMC: 2750944. DOI: 10.1208/ps060109. View

10.

Wang Y, Krzyzanski W, Doshi S, Xiao J, Perez-Ruixo J, Chow A . Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010; 12(4):729-40. PMC: 2976980. DOI: 10.1208/s12248-010-9234-9. View

11.

Grimm H . Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn. 2009; 36(5):407-20. DOI: 10.1007/s10928-009-9129-5. View

12.

Chakraborty A, Tannenbaum S, Rordorf C, Lowe P, Floch D, Gram H . Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012; 51(6):e1-18. PMC: 3584253. DOI: 10.2165/11599820-000000000-00000. View

13.

Kagan L . Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab Dispos. 2014; 42(11):1890-905. DOI: 10.1124/dmd.114.059121. View

14.

Luu K, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E . A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther. 2012; 341(3):702-8. DOI: 10.1124/jpet.112.191999. View

15.

Mager D, Krzyzanski W . Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22(10):1589-96. DOI: 10.1007/s11095-005-6650-0. View

16.

Wiczling P, Lowe P, Pigeolet E, Ludicke F, Balser S, Krzyzanski W . Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet. 2009; 48(12):817-26. DOI: 10.2165/11318090-000000000-00000. View

17.

Jager E, van der Velden V, Te Marvelde J, Walter R, Agur Z, Vainstein V . Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One. 2011; 6(9):e24265. PMC: 3168467. DOI: 10.1371/journal.pone.0024265. View

18.

Mager D, Mascelli M, Kleiman N, Fitzgerald D, Abernethy D . Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther. 2003; 307(3):969-76. DOI: 10.1124/jpet.103.057299. View

19.

Betts A, Clark T, Yang J, Treadway J, Li M, Giovanelli M . The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010; 333(1):2-13. DOI: 10.1124/jpet.109.164129. View

20.

Yan X, Lowe P, Fink M, Berghout A, Balser S, Krzyzanski W . Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. J Clin Pharmacol. 2011; 52(11):1624-44. PMC: 3483448. DOI: 10.1177/0091270011421911. View